Epidyolex and Sativex approved but progress is very limited Epidyolex and Sativex and Sativex have both been approved for NHS…
Nov 16
Feb 15
Alzheimer’s Research UK announces ‘cannabis-based’ Sativex trial for dementia
The UK’s leading dementia research charity Alzheimer’s Research UK has announced it will fund a “pioneering” clinical trial at King’s…
Nov 07
Jersey leaves UK mainland trailing as GPs are permitted to prescribe medical cannabis from February 2019
Jersey is often portrayed as a culturally backwards throwback to the 1950s but it has left mainland UK behind when…
Nov 02
Guidelines on prescribing cannabis products throw up range of barriers and hoops
With “cannabis-based” medicine becoming legal for specialist doctors to prescribe from 1 November, the Department for Health and Social Care…
Oct 05
Brain Cancer Patient Using Cannabis To Survive Denied Application To Expert Panel By Oncologists
In the latest example that suggests specialist doctors are unlikely to make life any easier for UK patients seeking medicinal…
Jul 27
Skunk #1 is used in Sativex: GW Pharmaceuticals’ Artificial Scarcity Revealed
New Scientist magazine has visited the GW Pharmaceuticals to interview Dr David Potter at the UK’s only legal cannabis farm,…
Apr 26
Brexit: How Will The EU Referendum Affect Cannabis Policy?
There are as many arguments as to leave or remain in the Union as there are people within the UK…
Dec 01
New drug Epidiolex by GW Pharmaceuticals gets FDA cinical trial approval for pediatric epilepsy
GW Pharmaceuticals; the company responsible for manufacturing Sativex, the cannabis extract in a spray bottle marketed for MS spasticity and…
Apr 23
Home Office Moves Sativex To Schedule 4 – Now In Effect
Sativex, the concentrated cannabis mouth spray, now has Schedule 4 status in England and Wales. This removes much of the…
Showing 9 of 9 posts